RELAY EU/US Subset: Ramucirumab Plus Erlotinib Improves Progression-Free Survival in First-Line EGFR Mutation-Positive NSCLC
No Thumbnail Available
Identifiers
Date
2019-10-01
Authors
Aix, S.
Novello, S.
Garon, E.
Nakagawa, K.
Nadal, E.
Moro-Sibilot, D.
Alonso Garcia, M.
Fabre, E.
Frimodt-Moller, B.
Zimmermann, A.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier science inc
Metrics
Export
Abstract
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
EU/US subset, EGFR-mutation positive NSCLC, Ramucirumab